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Epidemiology of 45,616 suspect 
cases of Hand, Foot and Mouth 
Disease in Chongqing, China,  
2011–2015
Jian Tao1,2, Xiao-yan He1, Yu Shi3, Guohun Zhu4, Shan Liu1, Zhenzhen Zhang5, Shi Tang1, 
Rong Zhang1, Bin Peng6, Zhidai Liu1, Junjie Tan1, Qian Chen1, Xingbin Wang1, Liming Bao1,7, 
Lin Zou1 & Penghui Zhang3
Epidemiology and etiology of hand, foot, and mouth disease (HFMD) based on large sample size or 
evaluation of detection for more enterovirus serotypes are not well investigated in Chongqing of China. 
45,616 suspect HFMD patients were prospectively enrolled among whom 21,615 were laboratory 
confirmed HFMD cases over a 5-year period (January 2011 to December 2015). Their epidemiological, 
clinical, and laboratory data were extracted and stratified by month, age, sex, disease severity, and 
enterovirus serotype. Subsequently 292 non-EV-A71/CV-A16 HFMD confirmed cases were randomly 
selected in three consecutive outbreaks to detect CV-A6 and CV-A10, using RT-PCR. Results showed 
that the HFMD epidemic peaked in early summer and autumn. The median age of onset was 2.45 years 
with a male-to-female ratio of 1.54:1, and with children under 5 years of age accounting for 92.54% 
of all confirmed cases. EV-A71 and CV-A16 infection accounted for only 36.05% (7793/21615) of total 
confirmed cases while EV-A71 accounted for 59.64% (232/389) of severe cases. Importantly, the 
proportion of EV-A71 infection generally increased with age which showed rapid growth in severe cases. 
CV-A6 and CV-A10 were tested positive in Chongqing, but CV-A6 had greater positive rates of 62.33% 
while CV-A10 had 4.79% in non-EV-A71/CV-A16 HFMD confirmed cases.
Hand, foot, and mouth disease (HFMD) is a common childhood infectious disease mainly caused by various 
human enteroviruses (EVs). EVs spread quickly through fecal-oral transmission but mostly cause HFMD in 
children under 5 years of age1. After EVs enter the intestine and break through the gut barrier to enter the blood, 
they are able to reach the spinal cord, brain, meninges, heart, liver, skin, nail and other organs thus causing 
relevant clinical symptoms. Most patients show self-limiting illness, typically fever, skin eruptions on palms, 
soles or buttocks, and vesicles in the mouth2. However, some patients rapidly develop neurological and systemic 
complications that can be fatal, such as acute flaccid paralysis, encephalitis, myocarditis, and encephalomyelitis3. 
Till so far, there is no specific treatment for HFMD, nor effective prevention of severe cases. Even HFMD vaccine 
designed for EV-A71 is commercially available in China since 20154, no reports on implementation of it or the 
reduction of HFMD cases due to it. Understanding its epidemiology and etiology is essential for controlling 
morbidity rates of HFMD.
EVs are members of the genus Enterovirus within the family Picornaviridae, order Picornavirales, which con-
sists of 4 species: EV-A, EV-B, EV-C, and EV-D5. To date, EVs comprise more than 100 serotypes, and prevalent 
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pathogens mainly distribute in EV-A and EV-B. Enterovirus A71 (EV-A71) and coxsackievirus A16 (CV-A16) of 
EV-A are widely considered to be typically the most common agents causing HFMD, and EV-A71 is the dominant 
causative pathogen in severe cases1. However, coxsackievirus A10 (CV-A10)6,7 and coxsackievirus A6 (CV-A6)8–15 
of EV-A have been increasingly reported worldwide in the past few years, which indicate that prevalent patho-
gens are diverse and shifting. Meanwhile, several atypical cutaneous manifestations of HFMD associated with 
CV-A616–20 have been described which has highlighted the necessity of virological surveillances to simultaneously 
detect additional EVs serotypes besides EV-A71 and CV-A16. However, there were no reports on the evaluation 
of simultaneous detection of CV-A6 and CV-A10 in the clinical laboratory center while only EV-A71, CV-A16 
and EVs universal (EVs) were detected conventionally.
The epidemiological character of HFMD in Chongqing was firstly described in 3,472 inpatients21. However, 
during the period 2011–2015, 21,615 out of 45,616 HFMD suspect patients admitted to The Children’s Hospital 
of Chongqing Medical University, who underwent laboratory etiological detection, were diagnosed as confirmed 
cases. The epidemiology and etiology of this large HFMD population remains unknown. Moreover, most patients 
with obvious HFMD clinical manifestations who contracted EVs tested positive and could not obtain causative 
EVs serotype identified in a clinical laboratory center.
In this study, 45,616 HFMD suspect cases received laboratory etiological detection and 21,615 confirmed 
HFMD patients were enrolled to characterize the epidemiology and etiology of HFMD, focusing on seasonal, age, 
gender and especially serotype patterns. Valuation of CV-A6 and CV-A10 identification was also investigated in 
other EVs positive cases with randomly collected samples in consecutive outbreaks from November 2015. This 
study evaluates the epidemic of HFMD based on large sample size and simultaneous detection for CV-A6 and 
CV-A10, which will help evaluate the effective protection of the EV-A71 vaccine against HFMD and the necessity 
of virological detection of more EVs serotypes other than EV-A71 and CV-A16 in clinical laboratories.
Materials and Methods
Case definitions. The diagnosis of HFMD was carried out and guided according to the criteria issued by 
the National Health and Family Planning Commission of the People’s Republic of China. Suspect HFMD cases 
were defined as patients with maculopapular or vesicular rash on the hand, foot, mouth, and buttocks with or 
without fever, while confirmed cases were defined as suspect case with laboratory confirmation of EVs infec-
tion (including EV-A71, CV-A16, or EVs) completed by RT-PCR assays. The confirmed cases with neurological 
complications (aseptic meningitis, encephalitis, encephalomyelitis, acute flaccid paralysis, or dysfunction of the 
autonomic nervous system), and cardiopulmonary complications (pulmonary edema, pulmonary hemorrhage, 
or cardiorespiratory failure, or both, were characterized as severe cases of HFDM, otherwise, patients were cate-
gorized as mild cases.
Sample collection and EVs detection. Depending on the symptoms and clinical status of suspect HFMD 
patients, we collected the appropriate clinical specimens, including throat swab, rectal swab, fecal sample, vesic-
ular fluid, or cerebrospinal fluid, and screened for EVs. RNA were extracted from the supernatants of the swab or 
stool specimens soaked in normal saline (NS) and dissolved in 30 μ l diethypyrocarbonate (DEPC) water. One-step 
RT-PCR assays were performed to detect EVs RNAs, using the EV-A71, CV-A16 and EVs test commercial kits 
(Sansure Biotech, China). Product performance indicators of diagnostic kit for EV-A71 (Registration number: 
20133400621), CV-A16 (Registration number: 20133400619), and EVs (Registration number: 20133400616) are 
the same as follows: Negative and positive coincidence rates are 100%, repeatability of intra and inter batch assays 
are good, variable coefficient of Ct value are all less than 10%, minimum detectable amount are 2.00E + 02 copies/
ml, and there is no cross reaction between other viruses with similar infection symptoms.
Clinical data collection. The Children’s Hospital of Chongqing Medical University is the designated center 
for HFMD diagnosis and treatment in Chongqing. HFMD suspect patients received laboratory etiological detec-
tion to identify laboratory confirmed cases between Jan 1, 2011, and Dec 31, 2015. The clinical and laboratory 
data was extracted from medical records, including basic demographic information (sex and date of birth), date 
of illness onset, duration of illness, symptoms, case classification (suspect or confirmed), severity (mild or severe), 
death status, date of symptoms onset, date of diagnosis, and date of death (if applicable), sample type (throat swab, 
rectal swab, fecal sample, vesicular fluid, or cerebrospinal fluid), and virus serotype (EV-A71, CV-A16 or EVs) 
for confirmed cases.
Non-EV-A71/CV-A16 sample collection and CV-A6/CV-A10 detection. On the day the laboratory 
test reports were issued, HFMD patients who tested EV-A71 and CV-A16 negative but EVs positive, were sorted 
out immediately. Their clinical specimens and RNA samples extracted for virological surveillances were sub-
sequently collected and stored at − 80 °C during the three HFMD outbreaks in November 2015, June 2016 and 
October 2016. A total of 292 eligible swab samples were randomly collected in these outbreaks for RNA extraction 
to avoid RNA samples for virological detection from degrading. Meanwhile, their RNA samples were collected for 
CV-A6/CV-A10 detection. One-step RT-PCRs were performed to detect CV-A6 and CV-A10, using the test com-
mercial kits (Sansure Biotech, China). Product performance indicators of diagnostic kit for CV-A6 and CV-A10 
were the same as those of EV-A71, CV-A16 and EVs.
Data Analysis. All the confirmed cases of the onset of HFMD illness from Jan 1, 2011, to Dec 31, 2015 
were enrolled in the analysis. We estimated the number of month-specific, age-specific, gender-specific and 
serotype-specific cases of HFMD by applying distribution in samples positive for the EVs in the corresponding 
year, respectively. To quantify seasonal patterns of HFMD by the month, we applied serotype-specific cases dis-
tribution in each month of the year. To quantify age patterns of HFMD, we applied age-specific cases distribution 
in each age group. To estimate proportions of each serotype pathogen in mild and severe HFMD cases according 
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to year and age group, we applied serotype-specific cases in proportion to the total positive cases of the corre-
sponding group. In CV-A6 and CV-A10 analysis, we estimated their positive rates in three consecutive HFMD 
outbreaks in November 2015, June 2016 and October 2016, respectively.
Ethics Statement. The study protocol was approved by the Institutional Review Board of the Children’s 
Hospital of Chongqing Medical University. The methods were carried out in accordance with the approved guide-
lines. Since this study was a retrospective analysis and all information were kept anonymous to protect patient 
confidentiality, written consents from the patients were waived.
Results
Total of 45,616 suspect HFMD cases were admitted in the Children’s Hospital of Chongqing Medical University 
during 2011–2015, of which 21,615 (47.38%) were laboratory confirmed cases and 389 (1.80%) were severe cases 
(Fig. 1). EV-A71, CV-A16 and other EVs co-circulated throughout the study period, and all of them had two 
outbreaks peaking in Spring and early Summer followed by a smaller peak in Autumn of each year (Fig. 2). The 
incidence of HFMD varied greatly with age, with the highest rates in children aged 0.5 to 4 years. The median 
age of reported cases was 2.45 years (range 1 month to 17 years). Most HFMD cases were in children younger 
than 5 years, accounting for 92.54% of all confirmed cases, and the incidence was very low in infants younger 
than 0.5 years and patients aged more than 5 years. Moreover, the one-year and three-year group accounted for 
19.09% and 22.56% respectively, followed by the two-year age group which accounted for the largest proportion 
of 29.56% (Fig. 3). The incidence of HFMD was higher in boys than that in girls throughout the five-year period 
with the male-to-female ratio (1.54:1) of all confirmed cases included in the study (Table 1).
Of 21,615 confirmed HFMD cases, the positive rate of EV-A71 and CV-A16 was 25.13% (5431/21615) and 
10.92% (2362/21615), respectively, whereas, other EVs dominated with 63.95% (13822/21615). The data for 
Figure 1. Flow diagram of HFMD patients in whom epidemiology and etiology were investigated. 
EV-A71 = enterovirus A71. CV-A16 = coxsackievirus A16. Other EVs = other enterovirus universal. 
*Cliassification according to the criteria issued by National Health and Family Planning Commission of the 
People’s Republic of China.
Figure 2. Monthly distribution and constituent ratio of enterovirus serotype associated with HFMD 
confirmed cases in Chongqing of China, 2011–2015. 
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each year from 2011 to 2015 showed a similar pattern: the infection ratios of EV-A71 were higher than those of 
CV-A16. “Other EVs” accounted for more than 50% infection ratio, as follows: 52.67% (2011), 62.81% (2012), 
70.85% (2013), 68.57% (2014), 59.39% (2015) correspondingly (Fig. 4A). In mild cases, other EVs were mainly 
pathogens (Fig. 4B), but in severe cases, EV-A71 was the main pathogen, accounting for 50.00% (2011), 54.55% 
(2012), 67.74% (2013), 60.36% (2014), 56.41% (2015) respectively (Fig. 4C).
Figure 3. Age distribution in HFMD confirmed cases in Chongqing of China, 2011–2015. 
HFMD confirmed cases, n (%)
2011 2012 2013 2014 2015
Month
 Jan 15 (0.66) 28 (0.64) 131 (3.68) 136 (2.15) 242 (4.76)
 Feb 9 (0.40) 28 (0.64) 47 (1.32) 88 (1.39) 88 (1.73)
 Mar 38 (1.67) 169 (3.87) 170 (4.77) 268 (4.24) 138 (2.71)
 Apr 230 (10.10) 328 (7.50) 375 (10.52) 791 (12.52) 526 (10.35)
 May 550 (24.15) 732 (16.74) 533 (14.96) 790 (12.50) 900 (17.71)
 Jun 464 (20.38) 648 (14.82) 492 (13.80) 865 (13.69) 1408 (27.70)
 Jul 223 (9.79) 445 (10.18) 336 (9.43) 435 (6.88) 611 (12.02)
 Aug 71 (3.12) 176 (4.03) 102 (2.86) 151 (2.39) 116 (2.28)
 Sep 45 (2.00) 184 (4.21) 205 (5.750 538 (8.51) 135 (2.66)
 Oct 228 (10.01) 605 (13.84) 431 (12.09) 1040 (16.46) 348 (6.85)
 Nov 282 (12.38) 574 (13.13) 399 (11.20) 808 (12.79) 395 (7.77)
 Dec 122 (5.36) 455 (10.41) 343 (9.62) 409 (6.47) 176 (3.46)
Age group
 < 0.5y 25 (1.10) 44 (1.01) 51 (1.43) 92 (1.46) 52 (1.02)
 0.5–1y 98 (4.30) 386 (8.83) 430 (12.07) 620 (9.81) 434 (8.54)
 1y 449 (19.72) 754 (17.25) 833 (23.37) 1016 (16.08) 1074 (21.13)
 2y 634 (27.84) 1158 (26.49) 862 (24.19) 2274 (35.99) 1461 (28.74)
 3y 618 (27.14) 1088 (24.89) 762 (21.38) 1219 (19.29) 1190 (23.41)
 4y 303 (13.31) 541 (12.37) 377 (10.58) 649 (10.27) 508 (9.99)
 5y 81 (3.56) 241 (5.51) 141 (3.96) 250 (3.96) 223 (4.39)
 6y 69 (3.03) 160 (3.66) 108 (3.03) 199 (3.15) 141 (2.77)
Sex
 Male 1410 (61.92) 2689 (61.51) 2169 (60.86) 3761 (59.52) 3061 (60.22)
 Female 867 (38.08) 1683 (38.49) 1395 (39.14) 2558 (40.48) 2022 (39.78)
Enterovirus serotype
 EV-A71 901 (39.57) 903 (20.65) 895 (25.11) 1376 (21.78) 1356 (26.68)
 CV-A16 177 (7.77) 723 (16.54) 144 (4.04) 610 (9.65) 708 (13.93)
 Other EVs 1199 (52.66) 2746 (62.81) 2525 (70.85) 4333 (68.57) 3019 (59.39)
Total 2277 (100.00) 4372 (100.00) 3564 (100.00) 6319 (100.00) 5083 (100.00)
Table 1.  Month, age, gender and serotype distribution of HFMD confirmed cases between 2011 and 
2015 in Chongqing of China. HFMD = hand, foot and mouth disease. EV-A71 = enterovirus A71. CV-
A16 = coxsackievirus A16. Other EVs = other enteroviruses universal.
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All the EVs subtypes were age-specific, mainly infecting children aged 0.5–4 years. In general, EV-A71 was the 
main pathogen in children aged 4 years and above, which accounted for more than CV-A16 in each age group, 
whereas, other EVs were the main pathogen in children under 4 years (Fig. 5A). It became obvious that the pro-
portion of EV-A71 and CV-A16 increased with age, but conversely the proportion of “other EVs” significantly 
decreased with age. EV-A71 increased from 18.08% to 48.40%, CV-A16 increased from 7.87% to 19.47%, “other 
EVs” decreased from 74.05% to 32.13% (Fig. 5B). In severe cases, EV-A71 was the main pathogen in children aged 
1 year and above, CV-A16 accounted for a few in each age group, “other EVs” was only dominant in infants under 
1 year (Fig. 6A). The trend of EV-A71 increased with age sharply, and increased to 100% in people aged more 
Figure 4. Proportions of enterovirus serotype in HFMD confirmed cases in Chongqing of China, 2011–
2015. (A) Based on total cases. (B) Based on mild cases. (C) Based on severe cases. EV-A71 = enterovirus A71. 
CV-A16 = coxsackievirus A16. Other EVs = other enterovirus universal.
www.nature.com/scientificreports/
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than 6 years. It is noteworthy that in children under 3 years old, “other EVs” has the highest percentage, which 
indicated other EVs were threating for severe HFMD in young children (Fig. 6B).
In 292 non-EV-A71/CV-A16 laboratory confirmed HFMD cases, 182 cases were detected CV-A6 positive and 
14 cases were detected CV-A10 positive without co-infection. 60% (30/50) were detected CV-A6 positive and 10% 
(5/50) were detected CV-A10 positive in the outbreak of November 2015, 12% (6/50) were detected CV-A6 posi-
tive and 8% (4/50) were detected CV-A10 positive in the outbreak of June 2016. 76.04% (146/192) were detected 
CV-A6 positive and 2.60% (5/192) were detected CV-A10 positive in the outbreak of October 2016 (Fig. 7). These 
results indicate that CV-A6 is highly prevalent in Chongqing with apparently season-varying, while CV-A10 
occasionally cause HFMD with low incidence all the time.
Discussion
HFMD is reported to have frequent outbreaks worldwide, especially in the Asian-Pacific region subsequent to 
the first reported outbreak in New Zealand in 1957. It was ranked as one of the infectious diseases with the 
highest incidence in China for five consecutive years, and was incorporated into the C class infectious diseases 
management in 2008. Our large-scale analysis of HFMD cases in Chongqing showed a bigger outbreak peak in 
Spring and a smaller one in Autumn without virus subtype-specific during 2011–2015. The main infectious age 
was in the 0.5–4 years and male children had a greater infections proportion. The EVs subtype distribution by 
age group was similar in both mild and severe HFMD cases. Their incidences increased with age until 2 years 
and then started to decrease. Children aged more than 6 years were seldom attacked by this disease, which was 
consistent with reports from other areas of China22–27. However, our results show that the HFMD population with 
the highest morbidity was the 2-year age group, which was different from the 1-year age group reported in the 
earlier epidemiology of HFMD21.
EV-A71 and CV-A16 have been widely considered to be the predominant pathogens and well-studied in 
HFMD cases in the past decades. Until 2015, the EV-A71 inactivated vaccine successfully entered the market in 
Figure 5. Enterovirus serotype distribution by age group in HFMD confirmed cases in Chongqing of 
China, 2011–2015. (A) Based on number of cases. (B) Based on proportion of serotypes.
www.nature.com/scientificreports/
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Figure 6. Enterovirus serotype distribution by age group in HFMD severe cases in Chongqing of China, 
2011–2015. (A) Based on number of cases. (B) Based on proportion of serotypes.
Figure 7. CV-A6 and CV-A10 detection in non-EV-A71 non-CV-A16 confirmed cases in three different 
outbreaks of November 2015, June 2016 and October 2016 in Chongqing of China. 
www.nature.com/scientificreports/
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China5. In our EVs subtype analysis, other EVs infection accounted for 63.94% in the total HFMD cases while 
EV-A71 infection accounted for only 25.13% and CV-A16 infection was only 10.92%, but in severe cases, EV-A71 
infection accounted for 59.64%. These results strongly emphasize that EV-A71 and CV-A16 are not the predom-
inant pathogens in Chongqing, but nevertheless, a sharp vigilance is necessary for EV-A71 infection control. 
Results of EV-A71 show that vaccination would be very helpful in the prevention of severe cases, but a bivalent or 
polyvalent vaccine would be desirable, in light of the co-circulation of non-EV-A71/CV-A16 EVs, that are respon-
sible for the highest proportion of HFMD morbidity and severe cases in patients within 1 year of age.
As demonstrated, both in our study and other reports28–30, the EV-A71 infection accounted for a large pro-
portion in severe cases. It was taken as an independent risk factor in the severity development at all times. EVs 
subtype distribution by age group in this study illustrated that the proportion of EV-A71 infection was positively 
correlated with age, whereas, the proportion of “other EVs” infections was negatively correlated with age. In addi-
tion, the proportion of EV-A71 infection reached a maximum proportion of 48.4% in the 5-year age group in mild 
cases, whereas it increased more sharply in severe cases, reaching a proportion of 92.3% in the 5-year age group 
and completely dominating in the 6-year age group. Both in mild and severe cases, most HFMD children under 1 
year were “other EVs” infected, thus demonstrating that morbidity in different causative respective infections, had 
different correlations with age. When evaluating the severity of HFMD, EVs subtype and age should be taken into 
consideration together as risk factors; neither could be considered independent risk factors if they are separated.
In recent years, numerous epidemiology studies in different areas proved that pathogens in circulation kept 
drifting8–15, which was likely the main reason why “other EVs” infections accounted for 63.94% in our study. 
Among “other EVs”, CV-A6 and CV-A10 emerged as the most prominent new pathogens. To investigate their 
epidemic proportions in Chongqing, we randomly collected 292 “other EVs” positive only samples, in three dif-
ferent outbreaks, for simultaneous detection of CV-A6 and CV-A10. 62.33% (182/292) were detected CV-A6 
positive and 4.79% (14/292) were detected CV-A10 positive without co-infection, which demonstrated that 
most non-EV-A71/CV-A16 laboratory confirmed HFMD cases could be accurately classified with simultane-
ously detecting CV-A6 and CV-A10. Noteworthy is the fact that CV-A6 positive cases accounted up for 60% 
and 76.04% of non-EV-A71/CV-A16 HFMD confirmed cases in the outbreak of November 2015 and October 
2016, respectively, but only 12% in the outbreak of June 2016. CV-A10 positive cases accounted for only 10%, 8% 
and 2.60% of non-EV-A71/CV-A16 HFMD confirmed cases in the outbreak of November 2015, June 2016 and 
October 2016. These results suggested that CV-A6 and CV-A10 were prevalent in this area. CV-A6 would be more 
likely to experience an outbreak while CV-A10 would remain relatively stable and occur sporadically.
CV-A6 infection should be considered in the differential diagnosis of an acute exacerbation of atopic derma-
titis (AD)31 and herpes zoster32, particularly in children, and specific warnings should be given to patients with 
CV-A6 infection because desquamation, onychomadesis or nail abnormalities can occur between one week to two 
months16–20. CV-A10 infection has most commonly been associated with more mild disease33 while infections with 
many other EVs serotypes may be severe and even fatal. Specific medications34–37 could be administered and actions 
taken on corresponding patients with risk factors38–42 while most mildly infected patients only need the expected 
conventional treatment. In our study, CV-A6/CV-A10 positive rates reached up to 67.12% in non-EV-A71/CV-A16 
HFMD laboratory confirmed cases. Therefore, CV-A6/CV-A10 detection should be incorporated into the conven-
tional etiologic test, which would be necessary in the different diagnosis and severity evaluation of HFMD.
Taking into account all these factors and findings, our study clearly demonstrates that causative EVs of HFMD 
is pluralistic. Simultaneously detecting CV-A6 and CV-A10 in a clinical laboratory in combination with EV-A71 
and CV-A16, could greatly enhance EVs subtype identification.
There are some limitations to the study. For example, most “other EVs” positive only samples between 2011 and 
2015 could not be collected. CV-A6 and CV-A10 analysis might show bias because of fewer samples and the short 
time duration, even though these results were consistent with clinical reports from other regions of China8–15. 
However, (1) the long-term virological surveillances of HFMD should be on going, and (2) a much broader range 
of EVs subtype diagnostic methods and kits are necessary in any further outbreaks of HFMD.
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